ReviewAnnual review of medicine2015
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
Review in Annual review of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 218 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
218 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders.Molecular psychiatry · 2018Pooled it
- Sustained pharmacodynamic effects of S-ketamine on cortical excitability and resting-state brain activity: A randomized, placebo-controlled trial.British journal of clinical pharmacology · 2026Trial
- Subacute effects of ketamine on neural correlates of reward processing.Translational psychiatry · 2026Trial
- Acute effects of intranasal esketamine application on thalamic structures in healthy individuals.The international journal of neuropsychopharmacology · 2025Trial
- Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression.Translational psychiatry · 2023Trial
- A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial.The American journal of psychiatry · 2022Trial
- Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression.Journal of affective disorders · 2022Trial
- A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance.Clinical and translational science · 2022Trial
- Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
- Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.The international journal of neuropsychopharmacology · 2021Trial
- A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
- Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study.Brain and behavior · 2020Trial
- Association between dynamic resting-state functional connectivity and ketamine plasma levels in visual processing networks.Scientific reports · 2019Trial
- Toward actionable biomarkers in psychiatry: a collaborative roadmap for precision clinical trials. An ACNP position paper.NPP - digital psychiatry and neuroscience · 2026Article
- Deacetyl xylopic acid exhibits synergistic antidepressant-like effects and augments fluoxetine activity in a chronic restraint-induced depression model in mice.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Anesthetics as emerging therapeutics for post-traumatic stress disorder (PTSD): bridging bench and bedside.Molecular psychiatry · 2026Review
- Limited Contribution of TMolecular imaging and biology · 2026Article
- Ionic Homeostasis Failure in Major Depressive Disorder: Ion Channel Mechanisms, Excitation-Inhibition Imbalance, and Precision Therapeutics.International journal of molecular sciences · 2026Review
- Amino Acid-Fatty Acid Profile as a Novel Predictive Method in the Assessment of Diagnosis and Treatment Efficacy of Anxiety-Related Disorders and Mood Disorders.International journal of molecular sciences · 2026Review
- Structural imaging predictors of ketamine response in treatment-resistant depression: a machine learning approach.Translational psychiatry · 2026Article
158 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Ketamine is the prototype for a new generation of glutamate-based antidepressants that rapidly alleviate depression within hours of treatment. Over the past decade, there has been replicated evidence demonstrating the rapid and potent antidepressant effects of ketamine in treatment-resistant depression. Moreover, preclinical and biomarker studies have begun to elucidate the mechanism underlying the rapid antidepressant effects of ketamine, offering a new window into the biology of depression and identifying a plethora of potential treatment targets. This article discusses the efficacy, safety, and tolerability of ketamine, summarizes the neurobiology of depression, reviews the mechanisms underlying the rapid antidepressant effects of ketamine, and discusses the prospects for next-generation rapid-acting antidepressants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.